LEGAL PROCEEDINGS (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended				37 Months Ended	1 Months Ended			9 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended
	May 31, 2008 Written plea agreement Biovail Pharmaceuticals, Inc.	May 31, 2008 Non-prosecution agreement Biovail Pharmaceuticals, Inc.	Sep. 30, 2009 Corporate Integrity Agreement Biovail Pharmaceuticals, Inc. Year	Oct. 31, 2009 General civil actions case	Oct. 31, 2009 General civil actions claim	Feb. 28, 2010 Glumetza Apotex Inc.	Jan. 31, 2009 Quetiapine AstraZeneca Pharmaceuticals LP month	Feb. 28, 2010 Aplenzin Watson month	Sep. 30, 2011 Aplenzin Watson patent action	Jan. 31, 2010 Aplenzin Paddock	Sep. 30, 2011 Aplenzin Paddock patent	Aug. 31, 2010 Aplenzin Par	Sep. 30, 2011 Aplenzin Par patent	Jun. 30, 2010 Wellbutrin XL Biovail Corporation	Dec. 31, 2009 Biovail Corporation defendant	Sep. 30, 2011 Tolmar month
Legal proceedings and other matters
Penalty fees	$ 22.2	$ 2.4
Obligation term (in years)			5
Dosage strength (in mg)						500 mg		174 mg and 348 mg		174 mg and 522 mg		174 mg and 348 mg		150 mg and 300 mg
Period of stay on approval (in months)							30	30								30
Number of actions consolidated into the first-filed case (in actions)									2
Number of the patents that remain in the litigation (in patents)									5
Number of patents listed in the FDA's Orange Book (in patents)											6		8
Number of cases settled (in cases)				3
Number of claims filed (in claims)					3
Number of other companies named as defendants (in defendants)															20